{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T16:12:44Z","timestamp":1779207164571,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:00:00Z","timestamp":1767484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"bayer hispania sl"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04174-8","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T11:18:52Z","timestamp":1767525532000},"page":"2360-2368","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient selection for triplet therapy with darolutamide in metastatic castration-sensitive prostate cancer and patterns of administration: a Spanish multicenter study"],"prefix":"10.1007","volume":"28","author":[{"given":"Teresa","family":"Alonso-Gordoa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ovidio","family":"Fern\u00e1ndez-Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ic\u00edar","family":"Garc\u00eda-Carbonero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"\u00c1lvarez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"S\u00e1nchez-Escribano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgia","family":"Anguera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ar\u00e1nzazu","family":"Gonz\u00e1lez-del-Alba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Gallardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Cacho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1lvaro","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen","family":"Perezagua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Zafra-Poves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Cassinello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejo","family":"Rodriguez-Vida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"L\u00f3pez-Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4973-3198","authenticated-orcid":false,"given":"Sergio","family":"V\u00e1zquez-Est\u00e9vez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,4]]},"reference":[{"key":"4174_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338\u201351.","journal-title":"N Engl J Med"},{"key":"4174_CR2","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352\u201360.","journal-title":"N Engl J Med"},{"key":"4174_CR3","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37:2974\u201386.","journal-title":"J Clin Oncol"},{"key":"4174_CR4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381:121\u201331.","journal-title":"N Engl J Med"},{"key":"4174_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1903307","volume":"381","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A, Chung BH, de Pereira Santana Gomes AJ, Given R, et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. 2019;381:13\u201324.","journal-title":"N Engl J Med"},{"key":"4174_CR6","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1200\/JCO.22.00193","volume":"40","author":"AJ Armstrong","year":"2022","unstructured":"Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, et al. Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2022;40:1616\u201322.","journal-title":"J Clin Oncol"},{"key":"4174_CR7","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1200\/JCO-24-01798","volume":"42","author":"F Saad","year":"2024","unstructured":"Saad F, Vjaters E, Shore N, Olmos D, Xing N, Pereira A, et al. Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial. J Clin Oncol. 2024;42:4271\u201381.","journal-title":"J Clin Oncol"},{"key":"4174_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","volume":"86","author":"D Tilki","year":"2024","unstructured":"Tilki D, van den Bergh RCN, Briers E, den Van Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II\u20142024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2024;86:164\u201382.","journal-title":"Eur Urol"},{"key":"4174_CR9","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","volume":"399","author":"K Fizazi","year":"2022","unstructured":"Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Flechon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet. 2022;399:1695\u2013707.","journal-title":"Lancet"},{"key":"4174_CR10","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","volume":"386","author":"MR Smith","year":"2022","unstructured":"Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med. 2022;386:1132\u201342.","journal-title":"N Engl J Med"},{"issue":"2","key":"4174_CR11","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.euf.2024.11.004","volume":"11","author":"B Hoeh","year":"2023","unstructured":"Hoeh B, Garcia CC, Wenzel M, Tian Z, Tilki D, Steuber T, et al. Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer: updated network meta-analysis stratified by disease volume. Eur Urol Focus. 2023;11(2):386\u201390.","journal-title":"Eur Urol Focus"},{"key":"4174_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.euf.2022.08.007","volume":"9","author":"P Mandel","year":"2023","unstructured":"Mandel P, Hoeh B, Wenzel M, Preisser F, Tian Z, Tilki D, et al. Triplet or doublet therapy in metastatic hormone-sensitive prostate cancer patients: a systematic review and network meta-analysis. Eur Urol Focus. 2023;9:96\u2013105.","journal-title":"Eur Urol Focus"},{"key":"4174_CR13","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","volume":"9","author":"IB Riaz","year":"2023","unstructured":"Riaz IB, Naqvi SAA, He H, Asghar N, Siddiqi R, Liu H, et al. First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis. JAMA Oncol. 2023;9:635\u201345.","journal-title":"JAMA Oncol"},{"key":"4174_CR14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.ejca.2022.07.011","volume":"173","author":"C Ciccarese","year":"2022","unstructured":"Ciccarese C, Iacovelli R, Sternberg CN, Gillessen S, Tortora G, Fizazi K. Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: a meta-analysis. Eur J Cancer. 2022;173:276\u201384.","journal-title":"Eur J Cancer"},{"key":"4174_CR15","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1080\/14796694.2025.2468569","volume":"21","author":"A Borque-Fernando","year":"2025","unstructured":"Borque-Fernando A, Alonso-Gordoa T, Juan-Fita MJ, Lopez Campos F, Perez-Fentes DA, Vilaseca A, et al. Beyond the status quo: when disease volume and metastatic timing are not enough to personalize treatment in mHSPC. Future Oncol. 2025;21:991\u20131003.","journal-title":"Future Oncol"},{"key":"4174_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102096","volume":"22","author":"F Paolieri","year":"2024","unstructured":"Paolieri F, Sammarco E, Ferrari M, Salfi A, Bonato A, Serafin D, et al. Front-line therapeutic strategy in metastatic hormone sensitive prostate cancer: an updated therapeutic algorithm. Clin Genitourin Cancer. 2024;22:102096.","journal-title":"Clin Genitourin Cancer"},{"key":"4174_CR17","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1001\/jamaoncol.2024.0591","volume":"10","author":"M Hussain","year":"2024","unstructured":"Hussain M, Fizazi K, Shore ND, Heidegger I, Smith MR, Tombal B, et al. Metastatic hormone-sensitive prostate cancer and combination treatment outcomes: a review. JAMA Oncol. 2024;10:807\u201320.","journal-title":"JAMA Oncol"},{"issue":"458\u201366","key":"4174_CR18","volume":"22","author":"M Kafka","year":"2024","unstructured":"Kafka M, Giannini G, Artamonova N, Neuwirt H, Ofner H, Kramer G, et al. Real-world evidence of triplet therapy in metastatic hormone-sensitive prostate cancer: an austrian multicenter study. Clin Genitourin Cancer. 2024;22(458\u201366):e1.","journal-title":"Clin Genitourin Cancer"},{"key":"4174_CR19","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1093\/jjco\/hyae098","volume":"54","author":"F Urabe","year":"2024","unstructured":"Urabe F, Imai Y, Goto Y, Tashiro K, Hashimoto M, Yoshihara K, et al. Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study. Jpn J Clin Oncol. 2024;54:1208\u201313.","journal-title":"Jpn J Clin Oncol"},{"key":"4174_CR20","unstructured":"European Medicines Agency. Nubeqa (darolutamide). SmPC. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nubeqa-epar-product-information_en.pdf. Accessed 25 Sept 2025."},{"key":"4174_CR21","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015;373:737\u201346.","journal-title":"N Engl J Med"},{"key":"4174_CR22","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","volume":"404","author":"A Bossi","year":"2024","unstructured":"Bossi A, Foulon S, Maldonado X, Sargos P, MacDermott R, Kelly P, et al. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design. Lancet. 2024;404:2065\u201376.","journal-title":"Lancet"},{"key":"4174_CR23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00041","author":"M Hussain","year":"2023","unstructured":"Hussain M, Tombal B, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial. J Clin Oncol. 2023. https:\/\/doi.org\/10.1200\/JCO.23.00041.","journal-title":"J Clin Oncol"},{"key":"4174_CR24","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","volume":"34","author":"S Halabi","year":"2016","unstructured":"Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, et al. Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol. 2016;34:1652\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"4174_CR25","first-page":"E25","volume":"19","author":"GT Gotto","year":"2025","unstructured":"Gotto GT, Yip SM, Shayegan B, O\u2019Sullivan DE, Wallis CJD, Basappa NS, et al. Practice patterns and predictors of treatment intensification in patients with metastatic castration-sensitive prostate cancer. Can Urol Assoc J. 2025;19(1):E25\u201335.","journal-title":"Can Urol Assoc J"},{"key":"4174_CR26","doi-asserted-by":"publisher","first-page":"8149","DOI":"10.3390\/curroncol30090591","volume":"30","author":"S Karim","year":"2023","unstructured":"Karim S, Lowther J, Gyulay G, O\u2019Sullivan D, Wallis CJD, Yip SM, et al. A real-world evidence study using Alberta-population-based data to describe treatment patterns for metastatic castration-sensitive prostate cancer patients (AWARENESS). Curr Oncol. 2023;30:8149\u201358.","journal-title":"Curr Oncol"},{"key":"4174_CR27","doi-asserted-by":"publisher","first-page":"447 e17","DOI":"10.1016\/j.urolonc.2024.07.002","volume":"42","author":"CJ Eule","year":"2024","unstructured":"Eule CJ, Kuna EM, Robin TP, Gershman B, Flaig TW, Kim SP. Treatment intensification in metastatic hormone-sensitive prostate cancer: an analysis of real-world practice patterns from the CancerLinQ database. Urol Oncol. 2024;42:447 e17-e24.","journal-title":"Urol Oncol"},{"key":"4174_CR28","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s11523-019-00674-0","volume":"14","author":"N Shore","year":"2019","unstructured":"Shore N, Zurth C, Fricke R, Gieschen H, Graudenz K, Koskinen M, et al. Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial. Target Oncol. 2019;14:527\u201339.","journal-title":"Target Oncol"},{"key":"4174_CR29","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3390\/cancers14040864","volume":"14","author":"NJ Nasser","year":"2022","unstructured":"Nasser NJ, Sun K, Scanlon KM, Mishra MV, Molitoris JK. Administering docetaxel for metastatic hormone-sensitive prostate cancer 1\u20136 days compared to more than 14 days after the start of LHRH agonist is associated with better clinical outcomes due to androgen flare. Cancers. 2022;14:864.","journal-title":"Cancers"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04174-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04174-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04174-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:32:25Z","timestamp":1779204745000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04174-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,4]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["4174"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04174-8","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,4]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Teresa Alonso-Gordoa reports writing assistance provided by Bayer Hispania, S.L.; a relationship with Eli Lilly and Company that includes board membership and speaking and lecture fees; a relationship with Ipsen SA that includes speaking and lecture fees; a relationship with Bayer Hispania, S.L that includes consulting or advisory and speaking and lecture fees; a relationship with Johnson & Johnson MedTech that includes consulting or advisory, funding grants, and speaking and lecture fees; a relationship with Astellas Pharma Inc that includes consulting or advisory; a relationship with Merck Serono SA that includes consulting or advisory and speaking and lecture fees; a relationship with Pfizer Inc that includes consulting or advisory and speaking and lecture fees; and a relationship with Novartis Pharma AG that includes consulting or advisory and speaking and lecture fees. Ovidio Fern\u00e1ndez-Calvo reports writing assistance provided by Bayer Hispania, S.L.; a relationship with Bayer Hispania, S.L., Janssen Pharmaceuticals Inc, Astellas Pharma Espa\u00f1a, Merck Sharp y Dohme Espa\u00f1a, Pfizer, Astra-Zeneca, BMS, Recordati, and Ipsen that includes consulting or advisory, non-financial support, and travel reimbursement. Ic\u00edar Garc\u00eda-Carbonero reports writing assistance provided by Bayer Hispania, S.L.; a relationship with Bayer Hispania, S.L that includes: travel reimbursement; and a relationship with Astellas Pharma Espa\u00f1a that includes: speaking and lecture fees. Sara \u00c1lvarez-Rodr\u00edguez reports writing assistance provided by Bayer Hispania, S.L.; a relationship with Astellas Pharma Espa\u00f1a that includes: speaking and lecture fees; a relationship with Janssen-Cilag SAS that includes speaking and lecture fees and travel reimbursement; and a relationship with Bayer Hispania, S.L that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Ricardo S\u00e1nchez-Escribano reports writing assistance provided by Bayer Hispania, S.L. Georgia Anguera reports writing assistance provided by Bayer Hispania, S.L. Ar\u00e1nzazu Gonz\u00e1lez-del-Alba reports writing assistance, non-financial support, speaking and lecture fees, and travel reimbursement provided by Bayer Hispania, S.L. Enrique Gallardo reports writing assistance provided by Bayer Hispania, S.L.; a relationship with Bayer Hispania, S.L., Astellas Pharma Espa\u00f1a, Ipsen, Pfizer, Eisai Inc., Recordati Rare Diseases, Merck Sharp y Dohme Espa\u00f1a, Bristol-Myers Squibb, and Astra Zeneca that includes consulting or advisory, funding grants, speaking and lecture fees, and travel reimbursement; a relationship with GSK that includes consulting or advisory and speaking and lecture fees; a relationship with Advanced Accelerator Applications Ib\u00e9rica SLU that includes consulting or advisory, funding grants, and speaking and lecture fees; a relationship with Laboratorios Farmac\u00e9uticos ROVI SA that includes: speaking and lecture fees; a relationship with LEO Pharma that includes: speaking and lecture fees and travel reimbursement; a relationship with Janssen Pharmaceuticals Inc and Merck KGaA that includes funding grants. Diego Cacho reports writing assistance provided by Bayer Hispania, S.L. Natalia Vidal reports writing assistance provided by Bayer Hispania, S.L.; a relationship with Astellas Pharma Inc, Ipsen Pharma SAS, Janssen Pharmaceuticals Inc that includes: consulting or advisory and speaking and lecture fees; and a relationship with MSD Merck Sharp & Dohme AG, Merck & Co Inc, Recordati Pharma GmbH, and Pfizer Inc that includes speaking and lecture fees and travel reimbursement. \u00c1lvaro Pinto reports writing assistance provided by Bayer Hispania, S.L.; and a relationship with Bayer Hispania, S.L., Janssen Pharmaceuticals Inc, Pfizer, and Astellas Pharma Europe Ltd that includes consulting or advisory. Carmen Perezagua reports writing assistance provided by Bayer Hispania, S.L.; and a relationship with Bayer Hispania, S.L that includes board membership. Marta Zafra reports writing assistance provided by Bayer Hispania, S.L. Javier Cassinello reports writing assistance provided by Bayer Hispania, S.L.; and a relationship with Bayer Hispania, S.L that includes non-financial support. Alejo Rodriguez-Vida reports writing assistance provided by Bayer Hispania, S.L.; and a relationship with Bayer Hispania, S.L that includes consulting or advisory. Fernando L\u00f3pez-Campos reports writing assistance provided by Bayer Hispania, S.L.; a relationship with Bayer Hispania, S.L, Astellas Pharma US Inc, and Johnson & Johnson Services Inc that includes board membership, consulting or advisory, funding grants, speaking and lecture fees, and travel reimbursement. Sergio V\u00e1zquez-Est\u00e9vez reports writing assistance provided by Bayer Hispania, S.L.; a relationship with Bayer Hispania, S.L that includes consulting or advisory, speaking and lecture fees, and travel reimbursement; a relationship with Astellas Pharma Espa\u00f1a, Novartis, and Pfizer that includes consulting or advisory and speaking and lecture fees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}